← Calendar
Readoutin 45d
Merck Sharp & Dohme LLC — Pembrolizumab
Phase 3 primary completion: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992).
- Date
- Jan 2027
- Type
- Readout
- Indication
- Urinary Bladder Neoplasms
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Merck Sharp & Dohme LLC
May2027
Readoutin 165d
Merck Sharp & Dohme LLC — Sacituzumab tirumotecanPhase 3 primary completion: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004).
May2027
Readoutin 165d
Merck Sharp & Dohme LLC — PembrolizumabPhase 3 primary completion: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012).
Jan2027
Readoutin 45d
Merck Sharp & Dohme LLC — 9vHPV VaccinePhase 3 primary completion: Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049).
Nov2026
Merck Sharp & Dohme LLC — PembrolizumabPhase 3 primary completion: Pembrolizumab (MK-3475) with chemoradiotherapy in MIBC (KEYNOTE-992).